ACILAC Drug Patent Profile
✉ Email this page to a colleague
When do Acilac patents expire, and what generic alternatives are available?
Acilac is a drug marketed by Nostrum Labs and is included in one NDA.
The generic ingredient in ACILAC is lactulose. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lactulose profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Acilac
A generic version of ACILAC was approved as lactulose by PHARM ASSOC on July 30th, 1996.
Summary for ACILAC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 30 |
Patent Applications: | 3,615 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ACILAC at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ACILAC
US Patents and Regulatory Information for ACILAC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nostrum Labs | ACILAC | lactulose | SOLUTION;ORAL, RECTAL | 073685-001 | May 28, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |